
Novartis, Boehringer DTC platforms slash prices for Cosentyx, Spiriva Respimat
In laying out their respective plans Monday to launch new direct-to-patient (DTP) platforms paring down the prices of popular medicines in the U.S., Novartis and Boehringer Ingelheim are falling in line with demands from President Donald Trump and joining …